Saudi Arabian pharmaceuticals
"The Saudi pharmaceutical sector is expected to maintain its strong growth momentum. However, a gradual shift towards low-cost generics coupled with stronger market penetration of global pharma players could lead to a redefinition of the competitive landscape", says Dr. Tobias Plate, Managing Partner and Regional Head at Roland Berger Strategy Consultants Middle East.
Currently, domestic pharmaceutical manufacturers account for a relatively small share of the market, currently 18%. While the government supports and encourages the build-up of local value chains, domestic players face two main challenges: Firstly, global pharma giants such as GlaxoSmithKline, Pfizer, Astellas and Sanofi Aventis are entering the market; secondly, low cost generics are becoming more prevalent.
"Consequently, domestic players – manufacturers in particular – must redefine their strategic positioning in the market and assess how to best capitalize on their capabilities in a changing environment", says Michael Caracache, Senior Project Manager at Roland Berger.
Key strategic levers for sustaining a competitive value proposition include redesigning value creation architecture, reconfiguring the business model, building brand equity and recalibrating the scope/scale of the activity coverage.